share_log

新興市場銘柄ダイジェスト:シンバイオ製薬、リッジアイがストップ高

Emerging Markets Digest: Shionogi Pharmaceuticals, Ridge Eye reached their limit up price.

Fisco Japan ·  Jun 11 15:21

<4019> Starting lineup 580 +7

Rising for 3 consecutive days. The engagement management platform service "TUNAG" announced that it has been adopted by Toho Gas Network and is regarded as good news. TUNAG is an application that can comprehensively implement measures to enhance engagement. Toho Gas spotlights workplaces and members who challenge such as new business development, expanding business areas, technology development, DX, etc. through the use of "TUNAG", and work and members who work diligently to ensure stable and safe urban gas supply by holding a web-based individual consultation service for those who hesitate to use the matching app or participate in events in the "R6 Marriage Support Matching Business Execution Business" of "R6 Marriage Support Matching Implementation Business" promoted by the Tokyo Metropolitan Government during the period from April 1, 2024 to March 31, 2025, and shares such actions throughout the company. We aim to enhance internal communication, improve engagement, and create a culture that promotes challenges and growth.

<6181> Tamany 159 +10

Significant rise. It was announced that the contract for entrusting the business related to individual consultations by web for people who are hesitant to use AI-based matching, use matching apps, or participate in events regarding the "R6 Marriage Support Matching Execution Business" during the period from April 1, 2024 to March 31, 2025 has been received from Tobu Top Tours, the business promoter of the "Tokyo Metropolitan Government Marriage Support Matching Business Promotion Service Contract". There is no change in the performance forecast for the year ending March 2025 at this time, but the company will continue to work in various ways to support marriage activities in local governments to revitalize local areas.

<4582> Shinbiopharmaceuticals 212 +50

Limit up. It is being bought on the basis of the material that the first case was registered on June 10, 2024 in the Phase IIa clinical trial of the injection Brincidofovir for cytomegalovirus infection after hematopoietic stem cell transplantation underway in the United States. The trial added cytomegalovirus infection as a new indication by changing the protocol as additional indications for the Phase IIa trial for adenovirus infection in immunodeficient states currently underway, which was accepted by the Food and Drug Administration (FDA) in February this year.

<4054> Japan Information C 607 +55

The stock continued to rise significantly. After the closing on the 10th day, it was announced that a share buyback capped at 200,000 shares (total purchase amount of 150 million yen), which is equivalent to 1.4% of the total number of issued shares (excluding treasury stock), will be implemented. The acquisition period is from June 12th to September 20th. The purpose is to conduct a flexible capital policy in response to changes in the business environment.

<5572> Ridge-i 2563 +500

Limit up. It was announced that the upward revision of the earnings forecast for the year ending July 2024 has been released. Sales are expected to exceed the plan due to the steady progress of existing customer projects and their enlargement in AI consulting and AI development services, as well as a large project for artificial satellite data AI analysis service. We are maintaining a high profitability ratio due to the increase in sales and the increase in profits by improving the profit margin due to the high utilization of in-house engineers and consultants.

<1436> Green Ena 2153 +246

Significantly up. In the financial results announced after the closing on the 10th, sales for the fiscal year ending April 24 were 9.676 billion yen, an increase of 9.3% compared to the previous year, and ordinary profit was 502 million yen, a decrease of 2.4% compared to the previous year. It is well received that sales hit a record high and net profit achieved the fourth consecutive increase. For the fiscal year ending April 25, sales are expected to increase by 18.9% compared to the previous year to 11.5 billion yen, and operating income is expected to expand to 560 million yen, up 11.4% from the previous year. At the same time, it was decided to increase the annual dividend for this fiscal year to 13 yen, up one yen from the previous year.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment